WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Dr. S.G. Maity and Dr. Asim Kumar Mandal*


The present study was planned to evaluate the clinical efficacy and
safety of Liv.52 DS tablets with UDCA in patients with Non-Alcoholic
Steatohepatitis in a randomized, comparative clinical study. A total of
35 patients aged between 18-65 years with Non-Alcoholic
Steatohepatitis characterized by elevated liver enzymes and
hepatomegaly with pain and discomfort in the right upper abdomen
and those who were willing to give informed consent were included in
the study. At the initial randomization visit, a detailed medical history
and symptomatic evaluation was done. In addition, examination
specific to the steatohepatitis with Hepatomegaly was also done. All
patients received liver screen (set of blood tests) including complete
haemogram, liver function tests and ultrasound abdomen. All the
patients were routinely screened and subjected to biochemical investigations. Biochemical
investigations included SGPT, SGOT, ALT, Serum Bilirubin, Total Protein, Albumin and
Globulin. Clinical examinations were repeated every four weeks for 12 weeks and
biochemical investigations were repeated only after 12 weeks. All the patients were
randomized arbitrarily using random table into either Liv.52 DS group (n=19) or UDCA
(n=16). The two groups were similar with regards to the demographic data, baseline
parameters and biochemical investigations. The Liv.52 DS group received 2 Tablets twice
daily and UDCA group received 600 mg thrice daily for 12 weeks. Statistical analysis was
carried out using GraphPad Prism Software, Version 4.01. All the patients completed the study and their data was available for analysis. Significant evidence of hepatoprotective effects of Liv.52 DS in patients with Non-Alcoholic Steatohepatitis in terms of clinical response and reduction in biochemical parameters were observed after 12 weeks of treatment. The clinical and biochemical recovery in Liv.52 DS group was faster as compared to UDCA group indicating the beneficial effect of Liv.52 DS tablets in patients with Non-Alcoholic Steatohepatitis. There were no clinically significant adverse reactions either reported or observed during the entire study period. The overall compliance to the treatment was good and no treatment discontinuations were reported. The results of the present study showing clinical benefit of Liv.52 DS appear promising in the management of Non-Alcoholic Steatohepatitis.

Keywords: Non-Alcoholic Steatohepatitis (NASH), Liv.52 DS, Ursdeoxycholic acid (UDCA), Non-Alcoholic Fatty Liver Disease (NAFLD).

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More